Canadian Network for Autoimmune Liver Disease
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jun 14, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Canadian Network for Autoimmune Liver Disease (CaNAL) is a study that aims to better understand rare liver diseases like Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH). These conditions can lead to serious health issues, such as liver failure or cancer. By gathering information from patients across Canada, this study hopes to create a comprehensive registry that tracks patient experiences, treatment responses, and long-term outcomes. This will help researchers identify risk factors and develop better diagnostic tools, ensuring patients receive timely and effective care.
To participate in this study, individuals must be 18 years or older and have a diagnosis of either PBC or AIH. Participants can expect to provide information about their health, undergo lab assessments, and share their quality of life experiences. The study is currently recruiting participants of all genders and aims to create a valuable resource for future research and clinical trials focused on these autoimmune liver diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis
- Exclusion Criteria:
- • Less than 18 years of age
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Saskatoon, Saskatchewan, Canada
Winnipeg, Manitoba, Canada
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Ottawa, Ontario, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Hamilton, Ontario, Canada
Montréal, Quebec, Canada
Sherbrooke, Quebec, Canada
Kingston, Ontario, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Bettina Hansen, PhD
Principal Investigator
University Health Network, Toronto General Hospital
Andrew Mason, MD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials